{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:53:38Z","timestamp":1777902818620,"version":"3.51.4"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["R42GM143986"],"award-info":[{"award-number":["R42GM143986"]}]},{"name":"National Institute of Health","award":["R42GM154550"],"award-info":[{"award-number":["R42GM154550"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glycans found on the ErbB family of receptors (HER1, HER2, and HER3) represent promising targets for cancer treatment. Characterization and full quantification of the bivalent kinetic interactions of therapeutic antibodies against the ErbB family of receptors directly in their native cancer cellular environment represent a unique strategy to help overcome cancer drug resistance and to the development of more effective therapeutic drugs. In this study, surface plasmon resonance microscopy (SPRM) was implemented in a unique and innovative manner to quantify the bivalent kinetic interactions of monoclonal antibodies targeting HER1 (EFGR), HER2 and HER3 directly on whole BXPC3 pancreatic cancer cells under a glycosylated (native) and deglycosylated cellular environment. Results revealed in unprecedented detail that both the single-arm affinity and double-arm stronger avidity modes of binding interaction could be observed. For bivalent Cetuximab (anti-HER1) KDs of 151\u00a0nM and 4.6\u00a0nM were observed, for bivalent Herceptin (anti-HER2) KDs of 2\u00a0nM and 0.1\u00a0nM were observed, and for bivalent anti-HER3 KDs of 13\u00a0nM and 1.3\u00a0nM were observed. However, upon enzymatic N-deglycosylation of BXPC3 cells, HER1 and HER3 demonstrated significant increase in affinity of 1000-fold and 21-fold, respectively. In contrast, HER2 kinetic interactions were negligibly influenced by cellular N-deglycosylation of BXPC3 cells. This study highlights for the first time SPRM\u2019s unique ability to characterize the bivalent heterogeneous kinetic interactions of monoclonal antibodies with ErbB receptors on whole cancer cells, and to quantify the shielding influence of pancreatic cancer cell surface N-glycosylation on these interactions.<\/jats:p>","DOI":"10.1093\/glycob\/cwaf066","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:17:05Z","timestamp":1760703425000},"source":"Crossref","is-referenced-by-count":1,"title":["Surface plasmon resonance microscopy reveals N-glycosylation driven modulation of affinity and avidity of ErbB receptors in whole single pancreatic cancer cells"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1752-7314","authenticated-orcid":false,"given":"Jes\u00fas S","family":"Aguilar D\u00edaz de le\u00f3n","sequence":"first","affiliation":[{"name":"Biosensing Instrument Inc. , 1007 E. Warner Rd, Tempe, Az, 85284 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Thirumurthy","sequence":"additional","affiliation":[{"name":"Biosensing Instrument Inc. , 1007 E. Warner Rd, Tempe, Az, 85284 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen","family":"Ly","sequence":"additional","affiliation":[{"name":"Biosensing Instrument Inc. , 1007 E. Warner Rd, Tempe, Az, 85284 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"2025120300363107700_ref1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.bbagen.2011.12.001","article-title":"Glycans as cancer biomarkers","volume":"1820","author":"Adamczyk","year":"2012","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2025120300363107700_ref2","doi-asserted-by":"publisher","first-page":"103811","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg Chem"},{"key":"2025120300363107700_ref3","doi-asserted-by":"publisher","first-page":"625084","DOI":"10.3389\/fphar.2021.625084","article-title":"Dual targeting EGFR and STAT3 with erlotinib and alantolactone Co-loaded PLGA nanoparticles for pancreatic cancer treatment","volume":"12","author":"Bao","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025120300363107700_ref4","doi-asserted-by":"publisher","first-page":"100057","DOI":"10.1074\/jbc.REV120.013168","article-title":"Fc \u03b3 receptor compositional heterogeneity: considerations for immunotherapy development","volume":"296","author":"Barb","year":"2021","journal-title":"J Biol Chem"},{"key":"2025120300363107700_ref5","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(00)00404-4","article-title":"Clinical trials of Herceptin\u00ae (trastuzumab)","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"2025120300363107700_ref6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/glycob\/cwx036","article-title":"The direct and indirect effects of glycans on immune function","volume":"27","author":"Baum","year":"2017","journal-title":"Glycobiology"},{"key":"2025120300363107700_ref7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/acs.jproteome.0c00521","article-title":"PD-L1 glycosylation and its impact on binding to clinical antibodies","volume":"20","author":"Benicky","year":"2021","journal-title":"J Proteome Res"},{"key":"2025120300363107700_ref8","doi-asserted-by":"publisher","first-page":"e17887","DOI":"10.1371\/journal.pone.0017887","article-title":"High affinity antigen recognition of the dual specific variants of Herceptin is entropy-driven in spite of structural plasticity","volume":"6","author":"Bostrom","year":"2011","journal-title":"PLoS One"},{"key":"2025120300363107700_ref9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1158\/1535-7163.MCT-06-0007","article-title":"Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity","volume":"5","author":"Buck","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2025120300363107700_ref10","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1158\/1078-0432.CCR-12-1785","article-title":"Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer","volume":"18","author":"Chandarlapaty","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025120300363107700_ref11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri","year":"2023","journal-title":"Cancers"},{"key":"2025120300363107700_ref12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/bjc.2016.116","article-title":"Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation","volume":"114","author":"Chugh","year":"2016","journal-title":"Br J Cancer"},{"key":"2025120300363107700_ref13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025120300363107700_ref14","doi-asserted-by":"publisher","first-page":"12031","DOI":"10.3390\/ijms241512031","article-title":"Binding affinity of trastuzumab and Pertuzumab monoclonal antibodies to extracellular HER2 domain","volume":"24","author":"Cruz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025120300363107700_ref15","doi-asserted-by":"publisher","first-page":"19395","DOI":"10.18632\/oncotarget.6283","article-title":"The role of N-glycans in colorectal cancer progression: potential biomarkers and therapeutic applications","volume":"7","author":"De Freitas-Junior","year":"2016","journal-title":"Oncotarget"},{"key":"2025120300363107700_ref16","doi-asserted-by":"publisher","first-page":"115317","DOI":"10.1016\/j.ab.2023.115317","article-title":"Glycan node profiling of soluble and membrane glycoproteins in whole cell lysates","volume":"680","author":"Aguilar D\u00edaz de le\u00f3n","year":"2023","journal-title":"Anal Biochem"},{"key":"2025120300363107700_ref17","doi-asserted-by":"publisher","first-page":"e0304154","DOI":"10.1371\/journal.pone.0304154","article-title":"Surface plasmon resonance microscopy identifies glycan heterogeneity in pancreatic cancer cells that influences mucin-4 binding interactions","volume":"19","author":"Aguilar D\u00edaz de le\u00f3n","year":"2024","journal-title":"PLoS One"},{"key":"2025120300363107700_ref18","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/glycob\/cwad078","article-title":"Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis","volume":"33","author":"Aguilar D\u00edaz de le\u00f3n","year":"2023","journal-title":"Glycobiology"},{"key":"2025120300363107700_ref19","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.7150\/jca.55526","article-title":"Oxidized-Desialylated low-density lipoprotein inhibits the antitumor functions of lymphokine activated killer cells","volume":"12","author":"Aguilar D\u00edaz de le\u00f3n","year":"2021","journal-title":"J Cancer"},{"key":"2025120300363107700_ref20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.25259\/Cytojournal_21_2025","article-title":"Aberrations in the glycosylation of receptor tyrosine kinases: a focus on lung adenocarcinoma","volume":"22","author":"Dmitrieva","year":"2025","journal-title":"Cytojournal"},{"key":"2025120300363107700_ref21","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1021\/acs.molpharmaceut.2c01047","article-title":"Live cells versus fixated cells: kinetic measurements of biomolecular interactions with the LigandTracer method and surface plasmon resonance microscopy","volume":"20","author":"Dong","year":"2023","journal-title":"Mol Pharm"},{"key":"2025120300363107700_ref22","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1038\/s41388-021-01801-w","article-title":"ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab","volume":"40","author":"Duarte","year":"2021","journal-title":"Oncogene"},{"key":"2025120300363107700_ref23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.trecan.2022.02.003","article-title":"Insights on ErbB glycosylation\u2013contributions to precision oncology","volume":"8","author":"Duarte","year":"2022","journal-title":"Trends Cancer"},{"key":"2025120300363107700_ref24","doi-asserted-by":"publisher","first-page":"15039","DOI":"10.1073\/pnas.1005025107","article-title":"Structural basis for high-affinity HER2 receptor binding by an engineered protein","volume":"107","author":"Eigenbrot","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120300363107700_ref25","doi-asserted-by":"publisher","first-page":"615565","DOI":"10.3389\/fmolb.2020.615565","article-title":"Binding revisited\u2014avidity in cellular function and Signaling","volume":"7","author":"Erlendsson","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2025120300363107700_ref26","doi-asserted-by":"publisher","first-page":"cwad100","DOI":"10.1093\/glycob\/cwad100","article-title":"Site-specific glycosylation analysis of epidermal growth factor receptor 2 (ErbB2): exploring structure and function toward therapeutic targeting","volume":"34","author":"Fujitani","year":"2024","journal-title":"Glycobiology"},{"key":"2025120300363107700_ref27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2025120300363107700_ref28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/diagnostics11040653","article-title":"The prognostic impact of her2 genetic and protein expression in pancreatic carcinoma\u2014her2 protein and gene in pancreatic cancer","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics"},{"key":"2025120300363107700_ref29","doi-asserted-by":"publisher","first-page":"17303","DOI":"10.1021\/acs.analchem.2c04324","article-title":"Microfluidically partitioned dual channels for accurate background subtraction in cellular binding studies by surface plasmon resonance microscopy","volume":"94","author":"Han","year":"2022","journal-title":"Anal Chem"},{"key":"2025120300363107700_ref30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.18869\/acadpub.rmm.1.3.6","article-title":"Minimal HER1 and HER2 expressions in CHO and HEK-293 cells cause them appropriate negative cells for HERs-related studies. Research","volume":"1","author":"Hosseinzadeh","year":"2013","journal-title":"Mol Med"},{"key":"2025120300363107700_ref31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4161\/cbt.23627","article-title":"Mechanisms of resistance to EGFR targeted therapies","volume":"14","author":"Hrustanovic","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"2025120300363107700_ref32","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-09-3321","article-title":"Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin","volume":"70","author":"Huang","year":"2010","journal-title":"Cancer Res"},{"key":"2025120300363107700_ref33","doi-asserted-by":"publisher","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of cell-surface antigen expression on target engagement and function of an epidermal growth factor receptor x c-MET bispecific antibody","volume":"290","author":"Jarantow","year":"2015","journal-title":"J Biol Chem"},{"key":"2025120300363107700_ref34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14712598.2019.1554052","article-title":"Mechanism of action of the trastuzumab biosimilar CT-P6","volume":"19","author":"Jeong","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025120300363107700_ref35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12935-021-02118-0","article-title":"[6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K\/AKT signaling","volume":"21","author":"Jiang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"2025120300363107700_ref36","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1111\/jcmm.16555","article-title":"Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR\/ERK pathway","volume":"25","author":"Jin","year":"2021","journal-title":"J Cell Mol Med"},{"key":"2025120300363107700_ref37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.csbj.2021.02.013","article-title":"Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2","volume":"19","author":"Kim","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2025120300363107700_ref38","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1038\/s41598-019-52507-9","article-title":"The biological activity of bispecific trastuzumab\/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells","volume":"9","author":"Komarova","year":"2019","journal-title":"Sci Rep"},{"key":"2025120300363107700_ref39","doi-asserted-by":"publisher","first-page":"7837","DOI":"10.1007\/s00216-018-1414-y","article-title":"Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing","volume":"410","author":"Lakayan","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"2025120300363107700_ref40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"2025120300363107700_ref41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"2025120300363107700_ref43","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/ijc.22423","article-title":"Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells","volume":"120","author":"Liu","year":"2007","journal-title":"Int J Cancer"},{"key":"2025120300363107700_ref44","article-title":"In-situ profiling of glycosylation on single cells with surface plasmon resonance imaging","volume":"16","author":"Xiaoyin","year":"2024","journal-title":"Nat Commun"},{"key":"2025120300363107700_ref45","volume-title":"Exploring affinity, avidity, and valency using SPRM","author":"Nguyen","year":"2025"},{"key":"2025120300363107700_ref46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fped.2015.00054","article-title":"Glycans instructing immunity: the emerging role of altered glycosylation in clinical immunology","volume":"3","author":"Lyons","year":"2015","journal-title":"Front Pediatr"},{"key":"2025120300363107700_ref47","doi-asserted-by":"publisher","first-page":"2149053","DOI":"10.1080\/19420862.2022.2149053","article-title":"Kinetic analysis of ternary and binary binding modes of the bispecific antibody emicizumab","volume":"15","author":"Mak","year":"2023","journal-title":"MAbs"},{"key":"2025120300363107700_ref48","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4049\/jimmunol.143.3.931","article-title":"Bivalent binding of an anti-CD3 antibody to Jurkat cells induces association of the T cell receptor complex with the cytoskeleton","volume":"143","author":"Marano","year":"1989","journal-title":"J Immunol"},{"key":"2025120300363107700_ref49","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1039\/C4AN02345E","article-title":"Comparative analysis of monoclonal antibody N-glycosylation using stable isotope labelling and UPLC-fluorescence-MS","volume":"140","author":"Mill\u00e1n Mart\u00edn","year":"2015","journal-title":"Analyst"},{"key":"2025120300363107700_ref50","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","article-title":"A genome-scale CRISPR screen identifies the ERBB and mTOR signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer","volume":"19","author":"Milton","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025120300363107700_ref51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccell.2023.12.002","article-title":"EGFR-activated myofibroblasts promote metastasis of pancreatic cancer","volume":"42","author":"Mucciolo","year":"2024","journal-title":"Cancer Cell"},{"key":"2025120300363107700_ref52","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3892\/ol.2019.9885","article-title":"The glycosylation landscape of pancreatic cancer","volume":"17","author":"Munkley","year":"2019","journal-title":"Oncol Lett"},{"key":"2025120300363107700_ref53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"2025120300363107700_ref54","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal growth factor receptor in pancreatic cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers"},{"key":"2025120300363107700_ref55","doi-asserted-by":"publisher","first-page":"103454","DOI":"10.1016\/j.critrevonc.2021.103454","article-title":"Hype or hope \u2013 can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC?","volume":"166","author":"Papini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025120300363107700_ref56","doi-asserted-by":"publisher","first-page":"43006","DOI":"10.1038\/srep43006","article-title":"Cellular glycosylation affects Herceptin binding and sensitivity of breast cancer cells to doxorubicin and growth factors","volume":"7","author":"Peiris","year":"2017","journal-title":"Sci Rep"},{"key":"2025120300363107700_ref57","first-page":"9610","article-title":"Label-free quantification of Nanoplastic\u2212cell membrane interaction by single cell deformation plasmonic imaging","volume":"19","author":"Li","year":"2025","journal-title":"Environ Sci Technol"},{"key":"2025120300363107700_ref58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-307","article-title":"Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients","volume":"11","author":"Petricevic","year":"2013","journal-title":"J Transl Med"},{"key":"2025120300363107700_ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13046-020-01823-4","article-title":"The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer","volume":"40","author":"Qian","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025120300363107700_ref60","doi-asserted-by":"publisher","first-page":"1914883","DOI":"10.1080\/19420862.2021.1914883","article-title":"Anti-tumoral activity of the pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models","volume":"13","author":"Rabia","year":"2021","journal-title":"MAbs"},{"key":"2025120300363107700_ref61","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","article-title":"Fc glycans of therapeutic antibodies as critical quality attributes","volume":"25","author":"Reusch","year":"2015","journal-title":"Glycobiology"},{"key":"2025120300363107700_ref62","doi-asserted-by":"publisher","first-page":"2361585","DOI":"10.1080\/19420862.2024.2361585","article-title":"Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn","volume":"16","author":"Reusch","year":"2024","journal-title":"MAbs"},{"key":"2025120300363107700_ref63","doi-asserted-by":"publisher","first-page":"e3096","DOI":"10.21769\/BioProtoc.3096","article-title":"Cluster analysis of endogenous HER2 and HER3 receptors in SKBR3 cells","volume":"8","author":"Roberts","year":"2018","journal-title":"Bio-protocol"},{"key":"2025120300363107700_ref64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13402-021-00606-z","article-title":"Terminal \u03b12,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells","volume":"44","author":"Rodrigues","year":"2021","journal-title":"Cell Oncol"},{"key":"2025120300363107700_ref65","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.3390\/ijms241311110","article-title":"An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma","volume":"24","author":"Rodriguez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025120300363107700_ref66","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid Tumors","volume":"71","author":"Rudnick","year":"2011","journal-title":"Cancer Res"},{"key":"2025120300363107700_ref67","doi-asserted-by":"publisher","first-page":"e70474","DOI":"10.1002\/cam4.70474","article-title":"Prevalence of HER3 expression in pancreatic cancer patients treated with systemic chemotherapy","volume":"13","author":"Satake","year":"2024","journal-title":"Cancer Med"},{"key":"2025120300363107700_ref68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"2025120300363107700_ref69","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41467-020-16309-2","article-title":"An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development","volume":"11","author":"Shankar","year":"2020","journal-title":"Nat Commun"},{"key":"2025120300363107700_ref70","doi-asserted-by":"publisher","first-page":"eaat5775","DOI":"10.1126\/scitranslmed.aat5775","article-title":"Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2\/CD3","volume":"10","author":"Slaga","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025120300363107700_ref71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/jpet.122.001554","article-title":"pH dependence of a GPR4 selective antagonist hampers its therapeutic PotentialS","volume":"386","author":"Stalewski","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2025120300363107700_ref72","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers13225746","article-title":"The EGF domains of MUC4 oncomucin mediate HER2 binding affinity and promote pancreatic cancer cell tumorigenesis","volume":"13","author":"Stoup","year":"2021","journal-title":"Cancers"},{"key":"2025120300363107700_ref73","doi-asserted-by":"publisher","first-page":"e0280590","DOI":"10.1371\/journal.pone.0280590","article-title":"Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of CC motif chemokine receptor-like 2 (CCRL2) ligand binding function","volume":"18","author":"Su","year":"2023","journal-title":"PLoS One"},{"key":"2025120300363107700_ref74","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.str.2015.06.015","article-title":"The structural role of antibody N-glycosylation in receptor interactions","volume":"23","author":"Subedi","year":"2015","journal-title":"Structure"},{"key":"2025120300363107700_ref75","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1111\/j.1742-4658.2008.06625.x","article-title":"Differential binding of human immunoagents and Herceptin to the ErbB2 receptor","volume":"275","author":"Troise","year":"2008","journal-title":"FEBS J"},{"key":"2025120300363107700_ref76","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-4-431-55381-6_11","volume-title":"Sugar chains","author":"Tsuboi","year":"2015"},{"key":"2025120300363107700_ref77","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.molonc.2014.05.003","article-title":"Acquired resistance to EGFR-targeted therapies in colorectal cancer","volume":"8","author":"Van Emburgh","year":"2014","journal-title":"Mol Oncol"},{"key":"2025120300363107700_ref78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","article-title":"Biological roles of glycans","volume":"27","author":"Varki","year":"2017","journal-title":"Glycobiology"},{"key":"2025120300363107700_ref79","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1038\/srep06609","article-title":"In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"2025120300363107700_ref80","doi-asserted-by":"publisher","first-page":"8463","DOI":"10.2147\/CMAR.S221877","article-title":"Emodin sensitizes human pancreatic cancer cells to egfr inhibitor through suppressing stat3 signaling pathway","volume":"Volume 11","author":"Wang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2025120300363107700_ref81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J Biomed Sci"},{"key":"2025120300363107700_ref82","doi-asserted-by":"publisher","first-page":"21295","DOI":"10.1073\/pnas.1211762109","article-title":"Heterobivalent ligands target cell-surface receptor combinations in vivo","volume":"109","author":"Xu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120300363107700_ref83","doi-asserted-by":"publisher","first-page":"15330338211019442","DOI":"10.1177\/15330338211019442","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection in colon cancer: validation research based on immunohistochemistry analysis","volume":"20","author":"Xu","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"2025120300363107700_ref84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13046-018-1015-9","article-title":"Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway","volume":"38","author":"Yang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2025120300363107700_ref85","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.kint.2016.12.012","article-title":"Deglycosylation of myeloperoxidase uncovers its novel antigenicity","volume":"91","author":"Yu","year":"2017","journal-title":"Kidney Int"},{"key":"2025120300363107700_ref86","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"2025120300363107700_ref87","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.analchem.5b02572","article-title":"Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging","volume":"87","author":"Zhang","year":"2015","journal-title":"Anal Chem"},{"key":"2025120300363107700_ref88","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of resistance to anti-EGFR therapy in colorectal cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"2025120300363107700_ref89","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/antib10010007","article-title":"Trastuzumab blocks the receiver function of HER2 leading to the population shifts of HER2-containing homodimers and heterodimers","volume":"10","author":"Zhao","year":"2021","journal-title":"Antibodies"},{"key":"2025120300363107700_ref90","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/anie.201908806","article-title":"Surface plasmon resonance microscopy: from single-molecule sensing to single-cell imaging","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Glycobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/glycob\/advance-article-pdf\/doi\/10.1093\/glycob\/cwaf066\/64790245\/cwaf066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/glycob\/article-pdf\/35\/12\/cwaf066\/64790245\/cwaf066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/glycob\/article-pdf\/35\/12\/cwaf066\/64790245\/cwaf066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:36:37Z","timestamp":1764740197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/glycob\/article\/doi\/10.1093\/glycob\/cwaf066\/8292993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/glycob\/cwaf066","relation":{},"ISSN":["1460-2423"],"issn-type":[{"value":"1460-2423","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,18]]},"article-number":"cwaf066"}}